CEACAM5 and hepatocellular carcinoma: YB-1/p18 was more powerful in detecting malignancies other than HCC compared to AFP, CEA or CA19-9 in patients with chronic liver disease (Figure 4C), and patients with a variety of malignancies with liver metastases tested predominantly positive for YB-1/p18 (Figure 1B, 3C).